Ovid’s Angelman syndrome therapy falls short at Phase 3
December 2, 2020Research and Development Angelman syndrome, Ovid
Ovid Therapeutics has revealed disappointing results for its therapy OV101 (gaboxadol) in the treatment of Angelman syndrome, admitting that it failed …
UK becomes first nation to approve Pfizer and BioNTech’s COVID-19 vaccine
December 2, 2020Research and Development, Sales and Marketing COVID-19, Pfizer, UK, Vaccine
The UK has become the first country worldwide to authorise Pfizer and BioNTech’s promising COVID-19 vaccine, the UK Government has …
The Autumn 2020 edition of Pharmafile is available to read for free online now!
December 1, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing infectious diseases, pharmafile, rare disease, respiratory
The Autumn 2020 edition of Pharmafile is available to read for free online now! 2020 has seen almost unprecedented disruption …
Eisai and Wren Therapeutics join forces to tackle neurodegenerative synucleinopathies
December 1, 2020Manufacturing and Production, Research and Development, Sales and Marketing Eisai, Wren Therapeutics
Eisai has forged an exclusive research partnership with Wren Therapeutics to develop new approaches in tackling neurodegenerative diseases known as …
EMA receives Pfizer and BioNTech’s filing for conditional approval of COVID-19 vaccine in Europe
December 1, 2020Manufacturing and Production, Sales and Marketing BioNTech, COVID-19, EMA, Pfizer, Vaccine
Pfizer and BioNTech have officially submitted their application to secure conditional marketing authorisation to the European Medicines Agency (EMA) for …
Grünenthal buys European rights to AstraZeneca’s Crestor for a potential $350m
December 1, 2020Manufacturing and Production, Sales and Marketing AstraZeneca, Crestor, Grunenthal
Grünenthal has picked up AstraZeneca’s statin therapy Crestor (rosuvastatin), currently approved in dyslipidaemia and hypercholesterolaemia treatment, in a deal worth …
Optimise your clinical trials with Avantor Clinical Services
December 1, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2020 Campaign, Avantor, clinical trials, expertise
Serious diseases like COVID-19 put increasing pressure on researchers to find breakthrough treatments faster. Along with accelerated timelines, biopharma and …
Cabometyx scores Japanese approval for unresectable hepatocellular carcinoma patients following systemic therapy
November 30, 2020Sales and Marketing Cabometyx, Japan, Takeda
The Japanese Ministry of Health, Labor and Welfare has awarded approval to Takeda for Cabometyx (cabozantinib) as a treatment for …
Analysis confirms Moderna’s COVID-19 vaccine efficacy to be 94.1%
November 30, 2020Research and Development, Sales and Marketing COVID-19, Moderna, Vaccine
US biotech Moderna has followed up on its highly promising efficacy data for its mRNA-based COVID-19 vaccine candidate with the …
Dupixent becomes first systemic medicine approved in Europe for children with severe atopic dermatitis
November 30, 2020Sales and Marketing Dupixent, EU, Europe, Sanofi
The European Commission has moved to expand the existing authorisation of Sanofi and Regeneron’s Dupixent (dupilumab) in the European Union …
UK secures another two million COVID-19 vaccine doses from Moderna
November 30, 2020Sales and Marketing COVID-19, Moderna, UK
The UK Government has expanded upon its previous negotiations with Moderna to secure an additional two million doses of its …
Japan approves AstraZeneca’s Forxiga for chronic heart failure
November 30, 2020Sales and Marketing AstraZeneca, Forxiga
Japan’s Ministry of Health, Labour and Welfare (MHLW) has announced the authorisation of AstraZeneca’s Forxiga as a treatment for chronic …
AstraZeneca targeted by suspected North Korean hackers
November 27, 2020Medical Communications
Hackers suspected to be operating from North Korea have tried to break into the systems of AstraZeneca, two people with …
Japan approves Astellas and FibroGen’s Evrenzo for chronic kidney disease patients currently not receiving dialysis
November 27, 2020Medical Communications, Sales and Marketing Astellas, Japan, fibrogen
Japan’s Ministry of Health, Labour and Welfare (MHLW) has passed approval for Astellas and FibroGen’s Evrenzo (roxadustat) in the treatment …
New trial expected for AstraZeneca’s COVID-19 vaccine
November 27, 2020Medical Communications
AstraZeneca is expected to launch new global trials to assess the efficacy of its COVID-19 vaccine using a lower dosage. …
EU fines Teva and Cephalon for keeping cheap sleep disorder medicine off the market
November 27, 2020Medical Communications
The European Union has fined Teva and Cephalon for colluding to keep a cheap alternative sleep disorder medicine off the …
Top Ten most popular articles on Pharmafile.com this week
November 27, 2020Medical Communications
The top ten news stories this week once again focus on COVID-19 treatments, with the Canadian Government securing 26,000 doses …
Y-mAbs announces FDA approval of Danyelza for the treatment of Neuroblastoma
November 26, 2020Business Services
Y-mAbs Therapeutics has announced that the FDA has approved Danyelza in combination with granulocyte-macrophage colony-stimulating factor (“GM-CSF”), for the treatment …
England COVID-19 spread levelling off after cases fell slightly
November 26, 2020Business Services
Coronavirus infection rates across England are levelling off after a slight decrease in cases last week, according to the Office …
Plan to import Canadian drugs to the US challenged by pharmaceutical lobby in Florida
November 26, 2020Business Services
The proposed plan to import cheaper Canadian drugs to Florida is being challenged by the US pharmaceutical lobby in court. …
Latest content
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?
